Plus   Neg

Stock Alert: Myovant Sciences Stock Up 4% In Premarket

Shares of Myovant Sciences Ltd. (MYOV) are rising over 4% in pre-market today, after the company announced that SPIRIT 2, the first of two Phase 3 studies of once-daily relugolix combination therapy in women with pain associated with endometriosis, met its co-primary efficacy endpoints and six key secondary endpoints.

In addition, relugolix combination therapy was generally well-tolerated including minimal bone mineral density loss over 24 weeks, the company said.

The stock has been trading in the range of $4.14 - $19.58 for the past one year, and closed Tuesday's trade at $11.58, up 2 cents or 0.17%. MYOV is currently trading at $12.15, up 57 cents or 4.92% in the pre-market trading session.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT